Literature DB >> 16696680

Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens.

P Hütt1, J Shchepetova, K Lõivukene, T Kullisaar, M Mikelsaar.   

Abstract

AIM: To develop in vitro assays for comparing the antagonistic properties and anti-oxidative activity of probiotic Lactobacillus and Bifidobacterium strains against various entero- and urinary pathogens. METHODS AND
RESULTS: The antagonistic activity of five probiotic lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus fermentum ME-3, Lactobacillus acidophilus La5, Lactobacillus plantarum 299v and Lactobacillus paracasei 8700:2) and two bifidobacteria (Bifidobacterium lactis Bb12, Bifidobacterium longum 46) against six target pathogens was estimated using different assays (solid and liquid media, anaerobic and microaerobic cultivation) and ranked (low, intermediate and high). Bacterial fermentation products were determined by gas chromatography, and the total anti-oxidative activity of probiotics was measured using linolenic acid test. Pyelonephritic Escherichia coli was highly suppressed by GG and both bifidobacteria strains. Lactobacilli strains 8700:2, 299v and ME-3 were the most effective against Salmonella enterica ssp. enterica in microaerobic while ME-3 and both bifidobacteria expressed high activity against Shigella sonnei in anaerobic milieu. Lact. paracasei, Lact. rhamnosus and Lact. plantarum strains showed intermediate antagonistic activity against Helicobacter pylori under microaerobic conditions on solid media. The highest anti-oxidative activity was characteristic for Lact. fermentum ME-3 (P < 0.05). No efficient antagonist against Clostridium difficile was found. The positive correlations between the pH, lactic acid production and anti-microbial activity for all tested probiotics were assessed.
CONCLUSIONS: Developed experimental assays enable to compare the anti-microbial and -oxidative activity of Lactobacillus and/or Bifidobacterium probiotics, which have been claimed to possess the ability of suppressing the growth of various enteric and urinary pathogens. SIGNIFICANCE AND IMPACT OF THE STUDY: Screening Lactobacillus and Bifidobacterium sp. strains according to their activity in various environmental conditions could precede the clinical efficacy studies for adjunct treatment with probiotics in cure of different gastrointestinal and urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696680     DOI: 10.1111/j.1365-2672.2006.02857.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  65 in total

1.  Antioxidative potential of lactobacilli isolated from the gut of Indian people.

Authors:  Anju A Achuthan; Raj Kumar Duary; Anupama Madathil; Harsh Panwar; Himanshu Kumar; Virender Kumar Batish; Sunita Grover
Journal:  Mol Biol Rep       Date:  2012-05-01       Impact factor: 2.316

2.  Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics.

Authors:  Piret Kõll; Reet Mändar; Imbi Smidt; Pirje Hütt; Kai Truusalu; Raik-Hiio Mikelsaar; Jelena Shchepetova; Kasper Krogh-Andersen; Harold Marcotte; Lennart Hammarström; Marika Mikelsaar
Journal:  Curr Microbiol       Date:  2010-05-05       Impact factor: 2.188

3.  Effects of cranberry extracts and ursolic acid derivatives on P-fimbriated Escherichia coli, COX-2 activity, pro-inflammatory cytokine release and the NF-kappabeta transcriptional response in vitro.

Authors:  Yue Huang; Dejan Nikolic; Susan Pendland; Brian J Doyle; Tracie D Locklear; Gail B Mahady
Journal:  Pharm Biol       Date:  2009       Impact factor: 3.503

4.  Diarrhoea associated with antibiotic use.

Authors:  Lynne V McFarland
Journal:  BMJ       Date:  2007-07-14

5.  A single intravesical instillation of Lactobacillus rhamnosus GG is safe in children and adults with neuropathic bladder: A phase Ia clinical trial.

Authors:  Catherine S Forster; Michael H Hsieh; Marcos Pérez-Losada; Ljubica Caldovic; Hans Pohl; Inger Ljungberg; Bruce Sprague; Crystal Stroud; Suzanne Groah
Journal:  J Spinal Cord Med       Date:  2019-05-17       Impact factor: 1.985

6.  Bifidobacterium--friend or foe? A case of urinary tract infection with Bifidobacterium species.

Authors:  Poonam Pathak; Cheryl Trilligan; Alwyn Rapose
Journal:  BMJ Case Rep       Date:  2014-09-24

7.  Probiotics modulate the Bifidobacterium microbiota of elderly nursing home residents.

Authors:  Sampo J Lahtinen; Liisa Tammela; Jaakko Korpela; Riikka Parhiala; Henri Ahokoski; Hannu Mykkänen; Seppo J Salminen
Journal:  Age (Dordr)       Date:  2008-11-28

Review 8.  Microbiota-mediated colonization resistance against intestinal pathogens.

Authors:  Charlie G Buffie; Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2013-10-07       Impact factor: 53.106

9.  Antimicrobial activity, inhibition of urogenital pathogens, and synergistic interactions between lactobacillus strains.

Authors:  Francisco O Ruiz; Gisela Gerbaldo; Paula Asurmendi; Liliana M Pascual; Walter Giordano; Isabel L Barberis
Journal:  Curr Microbiol       Date:  2009-11       Impact factor: 2.188

10.  Vaginal microbiota and the use of probiotics.

Authors:  Sarah Cribby; Michelle Taylor; Gregor Reid
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.